|

Daratumumab Clinical Trials

48 actively recruiting trials across 17 locations

Also known as: 945721-28-8, Anti-CD38 Monoclonal Antibody, Daratumumab Biosimilar HLX15, Daratumumab sc, Daratumumab-fihj +11 more

Pipeline

Early 1: 1Phase 1: 6Phase 2: 15Phase 3: 13Phase 4: 1Phase 1/2: 8Phase 2/3: 1

Top Sponsors

  • Mayo Clinic3
  • Janssen Research & Development, LLC3
  • AbbVie3
  • Pfizer2
  • City of Hope Medical Center2

Indications

  • Cancer48
  • Multiple Myeloma31
  • Refractory Multiple Myeloma3
  • Plasmablastic Lymphoma2
  • Relapsed Multiple Myeloma2

Other17 trials

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Phase 3
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Phase 1
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Phase 1/2
A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy
Phase 3
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Phase 3
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Phase 2
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma
Phase 3
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
Phase 2
Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
Phase 2
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
N/A
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
Phase 2
Risk Stratification and MRD-driven Maintenance for MM After ASCT
N/A
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
Phase 2
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Phase 2
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Phase 2
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Phase 4

Birmingham, Alabama4 trials

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

University of Alabama At Birmingham Hospital

Phase 1/2
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

University of Alabama at Birmingham

Phase 3
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

University of Alabama at Birmingham

Phase 2
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

University of Alabama at Birmingham Cancer Center

Phase 3

Gilbert, Arizona4 trials

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Site

Phase 3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Banner MD Anderson Cancer Center

Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Banner MD Anderson Cancer Center

Phase 3
Selinexor and Backbone Treatments of Multiple Myeloma Patients

Banner MD Anderson Cancer Center

Phase 1/2

Miami, Florida3 trials

A Study of Daratumumab

University of Miami Sylvester Cancer Center

Phase 3
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

University of Miami Miller School of Medicine

Early 1
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

University of Miami

Phase 2

Boston, Massachusetts3 trials

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Tufts Medical Center (Data Collection Only)

Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Massachusetts General Hospital

Phase 2
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Brigham and Women's Hospital

Duarte, California2 trials

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

City of Hope Medical Center

Phase 1

Los Angeles, California2 trials

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

University of Southern California /ID# 272414

Phase 1/2
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Valkyrie Clinical Trials

Phase 1/2

Denver, Colorado2 trials

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Colorado Blood Cancer Institute /ID# 279080

Phase 2/3
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Colorado Blood Cancer Institute /ID# 273129

Phase 1/2

Rochester, Minnesota2 trials

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Mayo Clinic in Rochester

Phase 1/2
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Mayo Clinic in Rochester

Phase 1

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Mobile, Alabama1 trial

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GSK Investigational Site

Phase 3

Phoeniz, Arizona1 trial

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma

Phoenix Children's Hospital

Phase 1

Scottsdale, Arizona1 trial

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Mayo Clinic in Arizona

Phase 2

Clovis, California1 trial

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Clovis Community Medical Center

Phase 3

La Jolla, California1 trial

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines

Phase 1

Washington D.C., District of Columbia1 trial

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Georgetown Lombardi Comprehensive Cancer Center

Phase 2

Atlanta, Georgia1 trial

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Emory Winship Cancer Institute

Phase 1/2

New York, New York1 trial

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Icahn School of Medicine at Mount Sinai

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.